| Triple-negative breast cancer—current status and future directions O Gluz, C Liedtke, N Gottschalk, L Pusztai, U Nitz, N Harbeck Annals of Oncology 20 (12), 1913-1927, 2009 | 796 | 2009 |
| Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade P Müller, M Kreuzaler, T Khan, DS Thommen, K Martin, K Glatz, S Savic, ... Science translational medicine 7 (315), 315ra188-315ra188, 2015 | 332 | 2015 |
| West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local … O Gluz, UA Nitz, M Christgen, RE Kates, S Shak, M Clemens, S Kraemer, ... Journal of Clinical Oncology, 2016 | 321 | 2016 |
| Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West … U Nitz, O Gluz, M Christgen, RE Kates, M Clemens, W Malter, B Nuding, ... Breast cancer research and treatment 165, 573-583, 2017 | 204 | 2017 |
| Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial O Gluz, UA Nitz, N Harbeck, E Ting, R Kates, A Herr, W Lindemann, ... Annals of oncology 19 (5), 861-870, 2008 | 172 | 2008 |
| The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical … PI Gonzalez‐Ericsson, ES Stovgaard, LF Sua, E Reisenbichler, Z Kos, ... The Journal of pathology 250 (5), 667-684, 2020 | 166 | 2020 |
| De-escalation strategies in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (BC): final analysis of the west german study group adjuvant dynamic … N Harbeck, O Gluz, M Christgen, RE Kates, M Braun, S Kueemmel, ... J. Clin. Oncol. 35 (26), 3046-3057, 2017 | 135 | 2017 |
| HER2 dimerization inhibitor pertuzumab-mode of action and clinical data in breast cancer N Harbeck, MW Beckmann, A Rody, A Schneeweiss, V Müller, T Fehm, ... Breast care 8 (1), 49-55, 2013 | 134 | 2013 |
| Lobular breast cancer: Clinical, molecular and morphological characteristics M Christgen, D Steinemann, E Kühnle, F Länger, O Gluz, N Harbeck, ... Pathology-Research and Practice 212 (7), 583-597, 2016 | 130 | 2016 |
| De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 … UA Nitz, O Gluz, M Christgen, EM Grischke, D Augustin, S Kuemmel, ... Annals of Oncology 28 (11), 2768-2772, 2017 | 127 | 2017 |
| AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2021 N Ditsch, C Kolberg-Liedtke, M Friedrich, C Jackisch, US Albert, ... Breast Care 16 (3), 214-227, 2021 | 120 | 2021 |
| West German study PlanB trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early … U Nitz, O Gluz, M Clemens, W Malter, T Reimer, B Nuding, B Aktas, ... Journal of clinical oncology 37 (10), 799-808, 2019 | 120 | 2019 |
| Comparison of neoadjuvant nab-paclitaxel+ carboplatin vs nab-paclitaxel+ gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results O Gluz, U Nitz, C Liedtke, M Christgen, EM Grischke, H Forstbauer, ... JNCI: Journal of the National Cancer Institute 110 (6), 628-637, 2018 | 113 | 2018 |
| WSG ADAPT–adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a … D Hofmann, U Nitz, O Gluz, RE Kates, T Schinkoethe, P Staib, N Harbeck Trials 14, 1-16, 2013 | 111 | 2013 |
| The prognostic impact of age in different molecular subtypes of breast cancer C Liedtke, A Rody, O Gluz, K Baumann, D Beyer, EB Kohls, K Lausen, ... Breast cancer research and treatment 152, 667-673, 2015 | 107 | 2015 |
| CDK4/6 inhibitors expand the therapeutic options in breast cancer: palbociclib, ribociclib and abemaciclib TK Eggersmann, T Degenhardt, O Gluz, R Wuerstlein, N Harbeck BioDrugs 33, 125-135, 2019 | 100 | 2019 |
| Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose–dense chemotherapy R Diallo-Danebrock, E Ting, O Gluz, A Herr, S Mohrmann, H Geddert, ... Clinical Cancer Research 13 (2), 488-497, 2007 | 99 | 2007 |
| Nuclear karyopherin α2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity O Gluz, P Wild, R Meiler, R Diallo‐Danebrock, E Ting, S Mohrmann, ... International journal of cancer 123 (6), 1433-1438, 2008 | 90 | 2008 |
| Personalized treatment of early-stage breast cancer: present concepts and future directions N Harbeck, M Salem, U Nitz, O Gluz, C Liedtke Cancer treatment reviews 36 (8), 584-594, 2010 | 84 | 2010 |
| Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression U Nitz, O Gluz, J Huober, HH Kreipe, RE Kates, A Hartmann, R Erber, ... Annals of oncology 25 (8), 1551-1557, 2014 | 69 | 2014 |
